Navigation Links
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
Date:4/17/2008

Berlin, Germany: A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today (Thursday 17 April). Dr. Angel Rodriguez, from the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA, said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumour-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment (treatment given before the primary surgery for the disease).

Dr. Rodriguez and colleagues studied 45 patients with locally advanced breast cancer in which the gene HER-2 was over-expressed. The patients received lapatinib for six weeks, followed by a combination of weekly trastuzumab and three-weekly docetaxel, given over 12 weeks, before primary surgery. Biopsies were performed at the time of diagnosis and also after six weeks of lapatinib and cells from the tumours were obtained and analyzed.

We saw significant tumour regression after six weeks of single agent lapatinib, said Dr. Rodriguez. Bi-dimensional tumour measurements showed a median decrease of minus 60.8%. We had previously showed that tumour-causing breast cancer stem cells were resistant to conventional preoperative chemotherapy; indeed, residual cancers that were exposed to such chemotherapy showed an increase in tumour-causing cells and enhanced tumour initiation by the formation of mammospheres, small tumours that form when tumour-causing cells are cultured in a test tube, which reflect the capacity of the cells to self-renew. So we were excited to see that the results with lapatinib were different.

Dr. Rodriguezs results suggest that specific signalling inhibitors of the pathways responsible for stem cell self-renewal could provide a poss
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Single-largest biodiversity survey says primary rainforest is irreplaceable
2. UNH becomes first university in nation to use landfill gas as primary energy source
3. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
4. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
5. Pregnant patients lose out in breast cancer treatment; a new approach is needed
6. Improving care and knowledge in translational research to fight breast cancer
7. Evidence now suggests eating soy foods in puberty protects against breast cancer
8. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
9. MU researcher links hormone replacement therapy to breast cancer
10. Gene variant increases breast cancer risk
11. High levels of estrogen associated with breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... -- In Brazil , cloud computing is ... solutions and 42 percent planning to invest in them by ... of the companies will be investing in these solutions for ... in the region are currently opting for the private cloud ... significant attention in the coming years. This trend is in ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... 13, 2008.-Unlike most scientific and technological advances, which tend ... finds itself the center of public debate and regulatory ... many of its applications. , In this second ... first was in 2003), the sample has been enlarged ...
... for humans in medical research, thanks to genomes that ... differently in mouse and man, a study by University ... reveals. Their results, which have implications for the ... in the current issue of the journal Proceedings of ...
... Md. (May 14, 2008) A study investigating aging in mice ... significantly less may help explain an already established phenomenon: a ... benefit that even regular exercise does not achieve. We ... many diseases, but key rodent studies tell us that being ...
Cached Biology News:BBVA Foundation international study on attitudes to stem cell research 2BBVA Foundation international study on attitudes to stem cell research 3BBVA Foundation international study on attitudes to stem cell research 4BBVA Foundation international study on attitudes to stem cell research 5BBVA Foundation international study on attitudes to stem cell research 6Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3Mouse study: When it comes to living longer, it's better to go hungry than go running 2Mouse study: When it comes to living longer, it's better to go hungry than go running 3Mouse study: When it comes to living longer, it's better to go hungry than go running 4
(Date:3/6/2015)... 6, 2015 According to a ... Product (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, ... Vaginal, Breast augmentation) - Global Forecast to 2019", published ... to reach $14.7 Billion in 2019 from $10.3 Billion ... 2014 to 2019. Browse 70 market ...
(Date:3/6/2015)... Minn. (PRWEB) March 06, 2015 ... Scientific Symposia sessions for the grain scientists’ Centennial ... abstracts. , 2015 marks the 100th anniversary ... Centennial Meeting in Minneapolis, Minnesota, U.S.A. on October ... from international researchers who are looking to the ...
(Date:3/6/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of Orexigen Therapeutics, Inc. ("Orexigen" or ... Such investors are advised to contact Peretz ... Eitan Kimelman at info@bgandg.com or ... and certain of its officers and/or directors have ...
(Date:3/6/2015)... 06, 2015 Global Specimen Solutions, ... focused on specimen management and informatics, announced today ... Specimen Solutions, Inc. is excited to catapult our ... that will further enhance our proprietary informatics tools ... specimen research. GSS has proved rapid market uptake ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. 2Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3
... Sigma-Aldrich (Nasdaq:,SIAL) today announced the publication of its ... of Visualized Experiments (JoVE).,This makes Sigma-Aldrich the first ... the traditional scientific publication process. Peer-reviewed,video protocols are ... the,efficiency of scientific communication and with it the ...
... CRY ),a biomaterials, medical device and tissue processing company, ... upcoming UBS Global Life,Sciences Conference at the Grand Hyatt ... Lee, executive vice president, chief operating officer and,chief financial ... 2:30 p.m., Eastern Time., CryoLife,s live presentation may ...
... BAX ), will host a quarterly conference call to ... 16, 2008, at,8:30 a.m. Eastern Time (7:30 a.m. Central ... or 703-639-1156 (international). Please dial,into the call at least ... for the,operator to connect you., This call is ...
Cached Biology Technology:Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 3CryoLife to Present at UBS Global Life Sciences Conference 2Baxter International Third Quarter 2008 Financial Results Conference Call 2
... of buffer and fixative results in ... In Vivo Manual Perfusion Fixation System ... buffer and fixative results in complete ... and clean--Complete system with everything down ...
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
... cells right in your 35mm dish ... dish Perfusion Chamber has separate openings ... dampen the fluctuations of the liquid ... prevent bubbles from entering the chamber. ...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
Biology Products: